Can you take Arcapta with Inotuzumab ozogamicin?

Inotuzumab ozogamicin has a moderate potential interaction with Arrhythmia.

The use of inotuzumab ozogamicin may cause increases in QT interval. It is recommended to administer inotuzumab ozogamicin with caution in patients with a history or predisposition for QTc prolongation, those taking medications that are known to prolong QT interval, and in patients with electrolyte disturbances. Obtain electrocardiograms and electrolytes values at baseline, after initiation of treatment, after initiation of drugs known to prolong QTc, and periodically thereafter as clinically indicated.

The indacaterol in Arcapta has a moderate potential interaction with Diabetes Mellitus.

Adrenergic bronchodilators may cause increases in blood glucose concentrations. These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended. Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis. Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.

Inotuzumab ozogamicin has a moderate potential interaction with Electrolyte Abnormalities.

The use of inotuzumab ozogamicin may cause increases in QT interval. It is recommended to administer inotuzumab ozogamicin with caution in patients with a history or predisposition for QTc prolongation, those taking medications that are known to prolong QT interval, and in patients with electrolyte disturbances. Obtain electrocardiograms and electrolytes values at baseline, after initiation of treatment, after initiation of drugs known to prolong QTc, and periodically thereafter as clinically indicated.

The indacaterol in Arcapta has a moderate potential interaction with Heart Disease.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

The indacaterol in Arcapta has a moderate potential interaction with High Blood Pressure.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

Inotuzumab ozogamicin has a major potential interaction with Hyperbilirubinemia.

Hepatotoxicity, including severe, life-threatening, and sometimes fatal hepatic veno-occlusive disease (VOD) may occur during or following treatment with inotuzumab ozogamicin. The risk of VOD is greater in patients who underwent hematopoietic stem cell transplant (HSCT) after inotuzumab ozogamicin treatment, total bilirubin level greater than or equal to the ULN before HSCT, ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a greater number of treatment cycles. Patients who have experienced prior VOD or have serious ongoing hepatic liver disease (e.g., cirrhosis, nodular regenerative hyperplasia, active hepatitis) are at an increased risk for worsening of liver disease, including developing VOD, following treatment with inotuzumab ozogamicin. Monitor closely for signs and symptoms of VOD; these may include elevations in total bilirubin, hepatomegaly (which may be painful), rapid weight gain, and ascites. It is recommended to monitor liver tests in all patients, including ALT, AST, total bilirubin, and alkaline phosphatase, before and following each dose of inotuzumab ozogamicin. Elevations of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of treatment.

The indacaterol in Arcapta has a moderate potential interaction with Hyperthyroidism.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

The indacaterol in Arcapta has a moderate potential interaction with Hypokalemia.

Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration. Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects. The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown. Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.

Inotuzumab ozogamicin has a major potential interaction with Liver Disease.

Hepatotoxicity, including severe, life-threatening, and sometimes fatal hepatic veno-occlusive disease (VOD) may occur during or following treatment with inotuzumab ozogamicin. The risk of VOD is greater in patients who underwent hematopoietic stem cell transplant (HSCT) after inotuzumab ozogamicin treatment, total bilirubin level greater than or equal to the ULN before HSCT, ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a greater number of treatment cycles. Patients who have experienced prior VOD or have serious ongoing hepatic liver disease (e.g., cirrhosis, nodular regenerative hyperplasia, active hepatitis) are at an increased risk for worsening of liver disease, including developing VOD, following treatment with inotuzumab ozogamicin. Monitor closely for signs and symptoms of VOD; these may include elevations in total bilirubin, hepatomegaly (which may be painful), rapid weight gain, and ascites. It is recommended to monitor liver tests in all patients, including ALT, AST, total bilirubin, and alkaline phosphatase, before and following each dose of inotuzumab ozogamicin. Elevations of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of treatment.

Inotuzumab ozogamicin has a moderate potential interaction with Renal Dysfunction.

The clearance of inotuzumab ozogamicin in patients with mild, moderate, or severe renal impairment was similar to patients with normal renal function. Care should be exercised when administering this agent in patients with end stage renal disease with or without hemodialysis as the safety and efficacy of inotuzumab ozogamicin is unknown in this patient population.

The indacaterol in Arcapta has a moderate potential interaction with Seizures.

Adrenergic bronchodilators may cause CNS stimulation. Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.